Alpha Teknova

Alpha Teknova

Alpha Teknova was founded in 1996 and completed its public listing on Nasdaq in 2021 under the ticker TKNO. The company operates what it describes as a make-to-stock model for ready-to-use biological buffers, cell-culture media, and protein purification reagents — consumables that bioprocessing customers treat as essential raw materials rather than commoditized lab supplies. The original manufacturing site in Hollister, California, handles liquid and dry-powder formulation. Teknova sells into cell and gene therapy, molecular diagnostics, and recombinant-protein production. Its revenue is concentrated in a small number of large accounts that include the top global vaccine and therapeutic developers. The company disclosed during IPO roadshow materials that approximately half its trailing revenue in 2021 was tied to COVID-19-related demand, with an aim to redeploy that manufacturing capacity toward the cell-and-gene-therapy pipeline as pandemic demand normalized. The customer list, though largely confidential, has included large pharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs). Its geography is heavily North America-weighted, with the California headquarters serving US and Canadian bioprocessing facilities. Teknova raised roughly $118 million in its June 2021 initial public offering, pricing shares at $15.00 (per the firm's S-1 filing and Nasdaq listing data, 2021). The company had approximately 300 employees at the time of its IPO. In May 2024, the firm announced the expansion of its GMP cleanroom capacity at the Hollister campus to support clinical-phase commercial readiness (per company press release, May 2024). This follows a broader industry trend of reagent suppliers vertically integrating to offer production-grade ancillary materials rather than just research-grade inputs. What differentiates Alpha Teknova structurally from broad-line life-sciences distributors is its narrow, high-cGMP-focus on a handful of consumable categories that feed directly into the final drug product. Unlike a general lab-products catalog, Teknova sells process-critical components — separation buffers, sugar feeds, pH stabilizers — where switching costs and regulatory requalification lock in long-term customer relationships. The company was controlled pre-IPO by private-equity backers Telegraph Hill Partners and was later joined by institutional holders such as Ampersand Capital Partners.